NASDAQ:KZIA Kazia Therapeutics (KZIA) Stock Price, News & Analysis $0.40 -0.01 (-2.42%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.39▼$0.4350-Day Range$0.19▼$1.2452-Week Range$0.19▼$1.58Volume1.21 million shsAverage Volume6.00 million shsMarket Capitalization$6.58 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Kazia Therapeutics alerts: Email Address Kazia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside396.8% Upside$2.00 Price TargetShort InterestBearish20.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.40) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 stars 3.5 Analyst's Opinion Consensus RatingKazia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKazia Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Kazia Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted20.69% of the outstanding shares of Kazia Therapeutics have been sold short.Short Interest Ratio / Days to CoverKazia Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kazia Therapeutics has recently increased by 7,076.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKazia Therapeutics does not currently pay a dividend.Dividend GrowthKazia Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KZIA. Previous Next 2.9 News and Social Media Coverage News SentimentKazia Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kazia Therapeutics this week, compared to 0 articles on an average week.Search Interest12 people have searched for KZIA on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Kazia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.89% of the stock of Kazia Therapeutics is held by institutions.Read more about Kazia Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kazia Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.33) per share.Price to Book Value per Share RatioKazia Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kazia Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Kazia Therapeutics Stock (NASDAQ:KZIA)Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.Read More KZIA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KZIA Stock News HeadlinesJuly 25 at 7:03 AM | investorplace.comBiotech Stock Laboratory: Try a Small Experiment With Kazia TherapeuticsJuly 12, 2024 | investorplace.comFrom Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode HigherJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.July 11, 2024 | investorplace.comKZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% GainsJuly 10, 2024 | investorplace.comWhy Is Kazia Therapeutics (KZIA) Stock Up 300% Today?July 10, 2024 | prnewswire.comKazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in GlioblastomaJune 27, 2024 | prnewswire.comKAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCERMay 24, 2024 | finanznachrichten.deKazia Therapeutics Limited: Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.May 23, 2024 | prnewswire.comKazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementMay 1, 2024 | prnewswire.comKAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSMarch 20, 2024 | morningstar.comKazia Therapeutics Ltd ADR KZIAMarch 16, 2024 | finance.yahoo.comKZIA Apr 2024 2.500 callMarch 13, 2024 | prnewswire.comKazia announces presentation of new data at AACR Annual MeetingFebruary 21, 2024 | msn.comWhat's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?February 21, 2024 | finanznachrichten.deKazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | finance.yahoo.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | prnewswire.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointSee More Headlines Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Next Earnings (Estimated)8/29/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KZIA CUSIPN/A CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+394.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick RatioN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales330.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book0.81Miscellaneous Outstanding Shares16,340,000Free Float16,178,000Market Cap$6.61 million OptionableOptionable Beta2.15 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. John Edwin Friend II (Age 54)M.D., CEO, MD & Director Comp: $731.34kMs. Gabrielle Heaton BBUS (ACC)CPA, Principal Accounting Officer, VP of Finance & Administration and Principal Financial OfficerMs. Anna SandhamCompany SecretaryKey CompetitorsBullfrog AINASDAQ:BFRGBiora TherapeuticsNASDAQ:BIORUnity BiotechnologyNASDAQ:UBXMEI PharmaNASDAQ:MEIPCocrystal PharmaNASDAQ:COCPView All Competitors KZIA Stock Analysis - Frequently Asked Questions How have KZIA shares performed this year? Kazia Therapeutics' stock was trading at $0.4395 at the beginning of the year. Since then, KZIA shares have decreased by 8.4% and is now trading at $0.4026. View the best growth stocks for 2024 here. How do I buy shares of Kazia Therapeutics? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kazia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP) and Pfizer (PFE). This page (NASDAQ:KZIA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.